Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

How accurate are stock forecasts?

Stock forecasts are based on technical and fundamental analysis but should not be considered as guaranteed predictions. Past performance does not guarantee future results.

How do I analyze SYRE stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate SYRE investment potential.

What is SYRE stock price today?

Get real-time SYRE stock price, historical data, and price charts on Financhill. Track SYRE performance with our advanced analysis tools.

Is SYRE a good investment?

Evaluate SYRE investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy SYRE stock?

To buy SYRE stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of SYRE?

View detailed market capitalization data and company valuation metrics for SYRE on our comprehensive analysis page.

What is the P/E ratio of SYRE?

Use our fundamental analysis tools to view SYRE P/E ratio and compare valuation metrics with industry peers.

What are SYRE earnings?

View SYRE earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Spyre Therapeutics, Inc. Stock Predictions

When an AI Platform Gets Pulled by Too Much Demand

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi

Buy

SYRE
Spyre Therapeutics, Inc.

Last Price:

$35.13

Seasonality Move:

-3.15%

7 Day Trial

ALL ACCESS PASS

$ 7

1.5 Million Users. Zero Hype. Still Private.

*DISCLOSURE: This is a paid advertisement for Immersed Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks immersed.com

Spyre Therapeutics, Inc. Stock Forecast

Over the next 52 weeks, Spyre Therapeutics, Inc. has on average historically risen by 10.7% based on the past 9 years of stock performance.
Spyre Therapeutics, Inc. has risen higher in 4 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 44.44%
Is Spyre Therapeutics, Inc. Stock Undervalued?

The current Spyre Therapeutics, Inc. [SYRE] share price is $35.12. The Score for SYRE is 53, which is 6% above its historic median score of 50, and infers lower risk than normal.
SYRE is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.

Will Spyre Therapeutics, Inc. Stock Go Up Next Year?

Over the next 52 weeks, Spyre Therapeutics, Inc. has on average historically risen by 10.7% based on the past 9 years of stock performance.

Spyre Therapeutics, Inc. Stock Rating

Buy

Spyre Therapeutics, Inc. (SYRE) is a Buy

Is Spyre Therapeutics, Inc. overpriced?

Spyre Therapeutics, Inc. has risen higher in 4 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 44.44%

Spyre Therapeutics, Inc. Stock Price History

Is SYRE stock going to rise?

Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SYRE is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:

NASDAQ

Country:

United States

Industry:

Biotechnology

Sector:

Health Care

Type:

stock

Website:

spyre.com

52-Week Data

52-Week High:

35.31

52-Week Low:

10.91

Prediction Charts

Market Cap:

2.7B

Price in USD:

35.12

Volume:

790.5K

Beta:

2.45

Technical Analysis

SMA50:

32.48

SMA100:

26.57

SMA200:

21.23

52-Wk Change:

47.19%

Stock Predictions

Is Spyre Therapeutics, Inc. stock public?

Yes, Spyre Therapeutics, Inc. is a publicly traded company.
What is the Spyre Therapeutics, Inc. stock quote today?

The Spyre Therapeutics, Inc. stock price is 35.12 USD today.
How to buy Spyre Therapeutics, Inc. stock online?

You can buy Spyre Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date	Opening	Closing	Minimum	Maximum
Jan-20	32.34	33.73	33.92	31.62
Jan-21	33.68	33.99	34.51	33.33
Jan-22	33.87	34.09	35.07	33.82
Jan-23	33.05	32.04	34.47	31.78
Jan-26	31.52	32.29	33.08	31.52
Jan-27	32.31	33.36	33.77	32.31
Jan-28	33.45	33.14	34.03	32.49
Jan-29	32.96	33.58	33.77	32.83
Jan-30	33.27	31.98	33.65	31.60
Feb-2	31.76	32.75	33.35	30.99
Feb-3	32.77	33.29	33.96	32.66
Feb-4	33.57	32.07	34.07	30.92
Feb-5	31.85	32.94	33.67	31.40
Feb-6	33.77	35.12	35.21	33.16

Spyre Therapeutics, Inc. Earnings

Spyre Therapeutics, Inc. Earnings Report: Per Share Spyre Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Spyre Therapeutics, Inc. Forecast Revenue Growth

Spyre Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Spyre Therapeutics, Inc. and historical quarterly revenue growth:

Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.68 per share, and a decrease next year of $0.05 per share.

* Spyre Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.